Search research articles
Contact Us
Filters
Showing results (31-40 of 58) with videos related to
Page
of 6
Sort By:
CA: a Cancer Journal for Clinicians
|
May 23, 2019
The current state of molecular testing in the treatment of patients with solid tumors, 2019
Wafik S El-Deiry, Richard M Goldberg, Heinz-Josef Lenz, et al.
Melanoma Research
|
January 6, 2016
BRAF inhibition for advanced locoregional BRAF V600E mutant melanoma: a potential neoadjuvant strategy
Sarah Sloot, Jonathan S Zager, Ragini R Kudchadkar, et al.
Cancer Medicine
|
January 9, 2026
Effects of Vemurafenib ± Cobimetinib on Intratumoral and Host Immunity in Patients With BRAFV600 Mutant Melanoma: Implications for Combination With Immunotherapy
Suthee Rapisuwon, Craig L Slingluff, Jennifer A Wargo, et al.
Melanoma Research
|
October 28, 2017
Resistance mechanisms to genetic suppression of mutant NRAS in melanoma
James P Robinson, Vito W Rebecca, David A Kircher, et al.
Gynecologic Oncology
|
June 11, 2024
A paradigm shift in understanding vulvovaginal melanoma as a distinct tumor type compared with cutaneous melanoma
Annelise M Wilhite, Sharon Wu, Joanne Xiu, et al.
Pigment Cell & Melanoma Research
|
February 5, 2014
Inhibition of autophagy enhances the effects of the AKT inhibitor MK-2206 when combined with paclitaxel and carboplatin in BRAF wild-type melanoma
Vito W Rebecca, Renato R Massaro, Inna V Fedorenko, et al.
The Journal of Biological Chemistry
|
February 13, 2014
p75 neurotrophin receptor cleavage by α- and γ-secretases is required for neurotrophin-mediated proliferation of brain tumor-initiating cells
Peter A Forsyth, Niveditha Krishna, Samuel Lawn, et al.
Pigment Cell & Melanoma Research
|
May 23, 2025
Comprehensive Profiling of Acral Lentiginous Melanoma Reveals Downregulated Immune Activation Compared to Cutaneous Melanoma
Stephanie J Wang, Joanne Xiu, Katherine M Butcher, et al.
Oncotargets and Therapy
|
September 19, 2017
Safety, pharmacokinetics, and pharmacodynamics of oral omaveloxolone (RTA 408), a synthetic triterpenoid, in a first-in-human trial of patients with advanced solid tumors
Ben C Creelan, Dmitry I Gabrilovich, Jhanelle E Gray, et al.
Melanoma Research
|
October 28, 2017
Vemurafenib treatment for patients with locally advanced, unresectable stage IIIC or metastatic melanoma and activating exon 15 BRAF mutations other than V600E
Sigrun Hallmeyer, Rene Gonzalez, David H Lawson, et al.
Page
of 6
Search research articles
Search
Showing results (31-40 of 58) with videos related to
Sort By:
Page
of 6
CA: a Cancer Journal for Clinicians
|
May 23, 2019
The current state of molecular testing in the treatment of patients with solid tumors, 2019
Wafik S El-Deiry, Richard M Goldberg, Heinz-Josef Lenz, et al.
Melanoma Research
|
January 6, 2016
BRAF inhibition for advanced locoregional BRAF V600E mutant melanoma: a potential neoadjuvant strategy
Sarah Sloot, Jonathan S Zager, Ragini R Kudchadkar, et al.
Cancer Medicine
|
January 9, 2026
Effects of Vemurafenib ± Cobimetinib on Intratumoral and Host Immunity in Patients With BRAFV600 Mutant Melanoma: Implications for Combination With Immunotherapy
Suthee Rapisuwon, Craig L Slingluff, Jennifer A Wargo, et al.
Melanoma Research
|
October 28, 2017
Resistance mechanisms to genetic suppression of mutant NRAS in melanoma
James P Robinson, Vito W Rebecca, David A Kircher, et al.
Gynecologic Oncology
|
June 11, 2024
A paradigm shift in understanding vulvovaginal melanoma as a distinct tumor type compared with cutaneous melanoma
Annelise M Wilhite, Sharon Wu, Joanne Xiu, et al.
Pigment Cell & Melanoma Research
|
February 5, 2014
Inhibition of autophagy enhances the effects of the AKT inhibitor MK-2206 when combined with paclitaxel and carboplatin in BRAF wild-type melanoma
Vito W Rebecca, Renato R Massaro, Inna V Fedorenko, et al.
The Journal of Biological Chemistry
|
February 13, 2014
p75 neurotrophin receptor cleavage by α- and γ-secretases is required for neurotrophin-mediated proliferation of brain tumor-initiating cells
Peter A Forsyth, Niveditha Krishna, Samuel Lawn, et al.
Pigment Cell & Melanoma Research
|
May 23, 2025
Comprehensive Profiling of Acral Lentiginous Melanoma Reveals Downregulated Immune Activation Compared to Cutaneous Melanoma
Stephanie J Wang, Joanne Xiu, Katherine M Butcher, et al.
Oncotargets and Therapy
|
September 19, 2017
Safety, pharmacokinetics, and pharmacodynamics of oral omaveloxolone (RTA 408), a synthetic triterpenoid, in a first-in-human trial of patients with advanced solid tumors
Ben C Creelan, Dmitry I Gabrilovich, Jhanelle E Gray, et al.
Melanoma Research
|
October 28, 2017
Vemurafenib treatment for patients with locally advanced, unresectable stage IIIC or metastatic melanoma and activating exon 15 BRAF mutations other than V600E
Sigrun Hallmeyer, Rene Gonzalez, David H Lawson, et al.
Page
of 6